UK-based Redx Pharma has closed a $36 million (€31 million) Series A financing round to support a Phase 2 trial of its Crohn’s disease drug candidate.
Tag Archive for: Redx
Jazz Pharmaceuticals plc has entered an agreement with Redx Pharma to acquire commercialisation rights to Redx KRAS blockers, which include G12D selective and pan-KRAS molecules.